The estimated Net Worth of Andrew Lawrence Filler is at least $260 mil dollars as of 15 May 2019. Mr. Filler owns over 1,200 units of Biosig Technologies Inc stock worth over $33,066 and over the last 7 years he sold BSGM stock worth over $0. In addition, he makes $226,500 as Independent Director at Biosig Technologies Inc.
Sign up
Mr. Filler BSGM stock SEC Form 4 insiders trading
Andrew has made over 2 trades of the Biosig Technologies Inc stock since 2018, according to the Form 4 filled with the SEC. Most recently he exercised 1,200 units of BSGM stock worth $4,500 on 15 May 2019.
The largest trade he's ever made was buying 14,518 units of Biosig Technologies Inc stock on 15 February 2018 worth over $21,051. On average, Andrew trades about 2,245 units every 65 days since 2017. As of 15 May 2019 he still owns at least 73,808 units of Biosig Technologies Inc stock.
You can see the complete history of Mr. Filler stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Andrew Filler biography
Andrew Lawrence Filler J.D. Esq. serves as Independent Director of the Company. Mr. Filler has served as our director since November 2017. Mr. Filler brings to BioSig over 20 years of experience in intellectual property for technology and medical device companies. He currently serves as partner and general counsel for Sherpa Technology Group since February 2014. In addition, Mr. Filler has served as general counsel and vice president of IP for Nanosys, Inc. from July 2004 until February 2014 and currently consults with Nanosys, Inc. on business and legal matters. Mr. Filler also served as chief intellectual property counsel at Caliper Technologies from January 2002 until June 2004, senior associate attorney at Weil, Gotshal & Manges from 1995 to 1997 and again from January 2000 until January 2002, and director of intellectual property at Corvascular from 1997 until 2000.
What is the salary of Andrew Filler?
As the Independent Director of Biosig Technologies Inc, the total compensation of Andrew Filler at Biosig Technologies Inc is $226,500. There are 6 executives at Biosig Technologies Inc getting paid more, with Kenneth Londoner having the highest compensation of $5,034,850.
What's Andrew Filler's mailing address?
Andrew's mailing address filed with the SEC is C/O BIOSIG TECHNOLOGIES, INC., 54 WILTON ROAD, 2ND FLOOR, WESTPORT, CT, 06880.
Insiders trading at Biosig Technologies Inc
Over the last 9 years, insiders at Biosig Technologies Inc have traded over $1,778,587 worth of Biosig Technologies Inc stock and bought 1,345,515 units worth $2,296,289 . The most active insiders traders include Kenneth L Londoner, Asher Holzer y Jerome B Zeldis. On average, Biosig Technologies Inc executives and independent directors trade stock every 24 days with the average trade being worth of $11,433. The most recent stock trade was executed by Kenneth L Londoner on 13 June 2023, trading 15,600 units of BSGM stock currently worth $19,344.
What does Biosig Technologies Inc do?
biosig technologies, inc. (otcqb: bsgm) is a medical device company that is developing a proprietary technology platform designed to greatly improve the $3 billion electrophysiology (ep) marketplace. led by a proven management team and a veteran, independent board of directors, minneapolis-based biosig is preparing to commercialize its pure ep system.
What does Biosig Technologies Inc's logo look like?
Complete history of Mr. Filler stock trades at Biosig Technologies Inc
Biosig Technologies Inc executives and stock owners
Biosig Technologies Inc executives and other stock owners filed with the SEC include:
-
Kenneth Londoner,
Executive Chairman of the Board, Chief Executive Officer -
Steven Chaussy,
Chief Financial Officer -
Kenneth L. Londoner M.B.A., MBA,
Founder, CEO & Exec. Chairman -
Samuel Navarro,
Independent Director -
Jeffrey O'Donnell,
Lead Independent Director -
Martha Pease,
Independent Director -
Andrew Filler,
Independent Director -
David Weild,
Independent Director -
Patrick Gallagher,
Independent Director -
Donald Foley,
Independent Director -
Anthony Zook,
Director -
Manasi Patwardhan,
Director of Strategic Planning -
Olivier Chaudoir,
Senior Director of Marketing -
Julie Stephenson,
Vice President - Clinical Affairs, Senior Director of Clinical Affairs -
Andrew Ballou,
Vice President - Investor Relations -
John Kowalski,
Vice President - Sales -
John Sieckhaus,
Chief Operating Officer -
Gray Fleming,
Chief Commercial Officer -
Steven Chaussy,
Chief Financial Officer -
Natasha Drapeau,
Exec. VP -
Brenda Castrodad,
Director of HR -
Lora Mikolaitis,
VP of Admin. -
Dr. Budimir S. Drakulic Ph.D.,
Chief Scientist -
Steven Eric Abelman,
Director -
Steve Chaussy,
Chief Financial Officer -
Roy T Tanaka,
Director -
Lora Mikolaitis,
10% owner -
Seth H. Z. Fischer,
Director -
Joseph Rafferty,
Chief Commercialization Offcr -
Jerome B Zeldis,
Director -
Asher Holzer,
Director -
Gregory D Cash,
President and CEO -
James L Klein,
Director -
James J Barry,
Director -
John Sieckhaus,
Chief Operating Officer -
Gray Fleming,
Chief Commercial Officer -
Steven J Buhaly,
Chief Financial Officer -
Frederick Hrkac,
Director -
Donald Browne,
Director -
Christopher Allen Baer,
Director